drugset / Trial / NCT00422890

Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

NCT00422890 ↗

Phase 3 Completed 10 enrolled Technical University Dresden
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Efficacy and safety of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation.

Timeline

Start
2007-01
Primary completion
2009-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — —